Blarkamesine correlates functional and cognitive outcomes in the AD-004 trial
Anavex Life Sciences presented new data from the ANAVEX®2-73-AD-004 Phase IIb/III program and the long-term open-label extension of ANAVEX®2-73-AD-EP-004 at the AD/PD 2026 conference, showing a consistent correlation between maintenance of MRI-defined brain volumes. A dedicated MRI biomarker analysis showed…











